<DOC>
	<DOCNO>NCT02000219</DOCNO>
	<brief_summary>The purpose study determine Oxalobacter formigenes effective lower plasma oxalate level patient primary hyperoxaluria dialysis .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Oxabact ( OC5 ) Primary Hyperoxaluria Patients Who Are Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Hyperoxaluria , Primary</mesh_term>
	<criteria>1 . Signed informed consent ( applicable age subject ) . A separate appendix inform consent sign patient participate substudy . 2 . Male female subject ≥ 2 year age . Subjects able swallow size 4 capsule twice daily 6 week , use gastric tube allow administration size 4 capsule . 3 . A diagnosis PH ( determine standard diagnostic method ) . 4 . Patient stable dialysis regimen least two week baseline . 5 . Predialysis plasma oxalate ≥40 micromole/L . 6 . Subjects receive vitamin B6 must receive stable dose least 3 month prior screen must remain stable dose study . Subjects receive vitamin B6 study entry must willing refrain initiate vitamin B6 study participation . 7 . Inability swallow size 4 capsule twice daily 6 week use gastric tube suit administration size 4 capsule via tube . 8 . Ongoing treatment immunosuppressive medication . 9 . The existence secondary hyperoxaluria , e.g . hyperoxaluria due bariatric surgery chronic gastrointestinal disease cystic fibrosis , chronic inflammatory bowel disease shortbowel syndrome . 10 . Use antibiotic O. formigenes sensitive ( see section 7.2.2 ) , include current antibiotic use , antibiotic use within 14 day initiate study medication . 11 . Current treatment separate ascorbic acid preparation . 12 . Pregnancy . 13 . Women childbearing potential use adequate contraceptive precaution . Sexually active female , unless surgically sterile least 2 year postmenopausal , must use highly effective contraception ( include oral , transdermal , injectable , implanted contraceptive , IUD , abstinence , use condom sexual partner sterile sexual partner ) 30 day prior first dose OC5 must agree continue use precaution clinical study . 14 . Presence medical condition Principal Investigator consider likely make subject susceptible adverse effect study treatment unable follow study procedure . 15 . Participation study investigational product , biologic , device , agent within 30 day prior first dose OC5 willing forego form investigational treatment study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>hyperoxaluria</keyword>
	<keyword>oxalate</keyword>
	<keyword>PH</keyword>
	<keyword>dialysis</keyword>
</DOC>